Evidence map›Paper›PMID 30922253›Full record

ArticleBMC cancer2019

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report.

Alexandre Harlé, Julie Guillet, Jacques Thomas, Jessica Demange, Gilles Dolivet, Didier Peiffert, Agnès Leroux, Xavier Sastre-Garau

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  5. Review
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alexandre HarléUniversité de Lorraine, Nancy, France.
Julie GuilletUniversité de Lorraine, Nancy, France.
Jacques ThomasService de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
Jessica DemangeService de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
Gilles DolivetCNRS, UMR, 7039 CRAN, Nancy, France.
Didier PeiffertUniversité de Lorraine, Nancy, France.
Agnès LerouxService de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
Xavier Sastre-GarauService de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France. xavier.sastreg@gmail.com.ORCID http://orcid.org/0000-0003-3942-0603
Institut de Cancérologie de Lorraine · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn clinical oncology, only a few applications have been developed using HPV as a personalized tumor marker, a lack most probably related to the limited information obtained by the classical Polymerase Chain Reaction (PCR) approach. To overcome this limitation, we have recently developed the capture-based Next-Generation Sequencing (NGS) "CaptHPV" assay, designed to provide an extensive and comprehensive molecular characterization of HPV DNA sequences associated with neoplasias, ie the sequence of the viral genome (245 genotypes), its physical state, viral load, integration site and genomic alterations at integration locus. These data correspond to highly specific tumor markers that can be used to improve diagnosis and patient's follow-up. CASE PRESENTATION: We report here a case that is a straightforward and practical illustration of the power of the CaptHPV method. A patient developed successively a carcinoma of the anal canal and of the tongue. The two tumors were squamous cell carcinoma, found associated with HPV16 using PCR. In order to document a possible metastasis to the tongue from the anal cancer, we performed CaptHPV analysis on the two tumors. The analysis of the anal carcinoma found 55 viral/human hybrid reads allowing the identification of the HPV16 DNA integration in the 4q25 chromosomal band locus with a 178,808 bp deletion in the cell genome. Molecular analysis of the tongue tumor disclosed 6110 reads of HPV16, with a viral pattern strictly identical to that of the anal tumor. A total of 131 hybrid reads between HPV16 and the cell genome were found, corresponding exactly to the same locus of integration of viral DNA at the 4q25 site. The 178,808 bp genomic deletion was also found in the lingual tumor. The exact identity of HPV insertional signatures in the two tumors, demonstrates unambiguously that the tongue tumor derived from the anal cancer whereas neither histological immunophenotyping nor classical viral analysis using PCR could allow a definitive diagnosis.

conclusionOur observation indicates that the establishment of a detailed cartography of HPV DNA sequences in a tumor specimen provides crucial information for the design of specific biomarkers that can be used for diagnostic, prognostic or predictive purposes.

Indexed as

Anus NeoplasmsBiomarkers, TumorCarcinoma, Squamous CellChromosomes, Human, Pair 4DNA, ViralHigh-Throughput Nucleotide SequencingHuman papillomavirus 16HumansMaleMiddle AgedPapillomavirus InfectionsSensitivity and SpecificitySequence Analysis, DNASequence DeletionTongue NeoplasmsVirus IntegrationBiomarkers, TumorDNA, ViralAnal carcinomaHead & neck carcinomaHPVTumor biomarkers

Identifiers

PMID30922253
PMCPMC6437879
OpenAlexW2940700580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.